Compare Mesoblast Limited (MESO) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Williams Companies Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Williams Companies Inc trades at $73.65 (market cap $90.70B). The key difference: Williams Companies Inc is far larger — about 41.8× Mesoblast Limited's market cap, and Williams Companies Inc pays a 2.83% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WMB | |
|---|---|---|
Market Cap | $2.17B | $90.70B |
Sector | Technology | Energy |
52-Week High | $20.96 | $79.40 |
52-Week Low | $12.88 | $56.51 |
Enterprise Value | $2.17B | $120.08B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
WMB trades at $74.57, up 1.62% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $11.95B in 2025 with a net income margin of 23.4% and recently secured a $5.34 billion Blackstone-led investment for power projects. Analyst consensus is strongly bullish with a $86.00 price target and 79% buy ratings.
The outlook is supported by strategic investments in energy infrastructure and stable cash flows, but risks include high debt levels and sensitivity to natural gas prices. The stock offers a dividend yield and growth potential from LNG expansion, though recent earnings misses warrant monitoring execution on new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
